Analyst Serge Belanger of Needham maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), retaining the price target of $19.00.
Serge Belanger has given his Buy rating due to a combination of factors surrounding Liquidia Technologies. One primary reason is the strong potential for Yutrepia’s approval by the FDA for the treatment of both PAH and PH-ILD by mid-2025, which is seen as a significant milestone for the company. The market for these pulmonary conditions is expected to expand substantially, reaching about $2 billion by that time, and potentially growing to between $3 billion and $4 billion by 2030.
Additionally, Yutrepia is believed to offer notable advantages over existing treatments, such as a better inhaler device, the ability to deliver higher doses, improved patient tolerance, and possibly greater treatment durability. The regulatory delay that previously impacted the stock’s performance now provides an opportunity to accumulate more clinical data through ongoing trials, further showcasing Yutrepia’s benefits. These factors collectively underscore the potential for Liquidia Technologies to capitalize on a growing market, justifying the Buy rating.
In another report released on December 25, BTIG also maintained a Buy rating on the stock with a $29.00 price target.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Liquidia Technologies (LQDA) Company Description:
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
Read More on LQDA:
